Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults
Go back to Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 9.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.00 | 52 Week High | $9.23 | |||
| Open | $9.00 | 52 Week Low | $1.16 | |||
| Day High | $9.00 | P/E | N/A | |||
| Day Low | $9.00 | EPS | $-0.30 | |||
| Volume | 5,058 | |||||
